Human autoantibodies underlying infectious diseases - Archive ouverte HAL Access content directly
Journal Articles Year : 2022

Human autoantibodies underlying infectious diseases

(1, 2) , (1, 2, 3) , (1, 2, 4) , (1, 2, 3, 5)
1
2
3
4
5

Abstract

The vast interindividual clinical variability observed in any microbial infection—ranging from silent infection to lethal disease—is increasingly being explained by human genetic and immunological determinants. Autoantibodies neutralizing specific cytokines underlie the same infectious diseases as inborn errors of the corresponding cytokine or response pathway. Autoantibodies against type I IFNs underlie COVID-19 pneumonia and adverse reactions to the live attenuated yellow fever virus vaccine. Autoantibodies against type II IFN underlie severe disease caused by environmental or tuberculous mycobacteria, and other intra-macrophagic microbes. Autoantibodies against IL-17A/F and IL-6 are less common and underlie mucocutaneous candidiasis and staphylococcal diseases, respectively. Inborn errors of and autoantibodies against GM-CSF underlie pulmonary alveolar proteinosis; associated infections are less well characterized. In individual patients, autoantibodies against cytokines preexist infection with the pathogen concerned and underlie the infectious disease. Human antibody-driven autoimmunity can interfere with cytokines that are essential for protective immunity to specific infectious agents but that are otherwise redundant, thereby underlying specific infectious diseases.

Dates and versions

hal-03693852 , version 1 (13-06-2022)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Anne Puel, Paul Bastard, Jacinta Bustamante, Jean-Laurent Casanova. Human autoantibodies underlying infectious diseases. 2022, 219 (4), ⟨10.1084/jem.20211387⟩. ⟨hal-03693852⟩
6 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More